Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Assets: 2021-2025

Historic Non-Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $9.4 million.

  • Amylyx Pharmaceuticals' Non-Current Assets rose 71.71% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 71.71%. This contributed to the annual value of $4.2 million for FY2024, which is 92.04% down from last year.
  • Amylyx Pharmaceuticals' Non-Current Assets amounted to $9.4 million in Q3 2025, which was up 21.41% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Non-Current Assets registered a high of $52.8 million during Q4 2023, and its lowest value of $663,000 during Q4 2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Non-Current Assets had a median value of $7.7 million in 2025 and averaged $15.7 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Non-Current Assets surged by 1,305.73% in 2022 and then plummeted by 92.04% in 2024.
  • Amylyx Pharmaceuticals' Non-Current Assets (Quarterly) stood at $663,000 in 2021, then skyrocketed by 1,305.73% to $9.3 million in 2022, then skyrocketed by 466.39% to $52.8 million in 2023, then tumbled by 92.04% to $4.2 million in 2024, then skyrocketed by 71.71% to $9.4 million in 2025.
  • Its last three reported values are $9.4 million in Q3 2025, $7.7 million for Q2 2025, and $3.5 million during Q1 2025.